LENZ Therapeutics, Inc.(LENZ) - 2024 Q2 - Quarterly Results

Exhibit 99.1 LENZ Therapeutics Reports Second Quarter 2024 Financial Results Submitted New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for LNZ100 for the treatment of presbyopia Announced positive topline and capstone data from the Phase 3 CLARITY study Strengthened financial position with $30 million private placement from Ridgeback Capital in July 2024 Pro forma cash, cash equivalents and marketable securities, inclusive of the private placement, were$226.2 million as of June 30 ...